Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials

PURPOSE: The purpose of this study was to compare the efficacy and safety of brexpiprazole 4 mg/day (B4) and 2 mg/day (B2) for treating acute schizophrenia. PATIENTS AND METHODS: We performed three categorical meta-analyses (B4 vs placebo, B2 vs placebo, and B4 vs B2) of double-blind, randomized pla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuropsychiatr Dis Treat
Autors principals: Kishi, Taro, Oya, Kazuto, Matsui, Yuki, Nomura, Ikuo, Sakuma, Kenji, Okuya, Makoto, Matsuda, Yuki, Fujita, Kiyoshi, Funahashi, Toshihiko, Yoshimura, Reiji, Iwata, Nakao
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6171755/
https://ncbi.nlm.nih.gov/pubmed/30319261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S176676
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars